Jazz Pharmaceuticals EBITDA 2010-2024 | JAZZ

Jazz Pharmaceuticals EBITDA for the quarter ending September 30, 2024 was $0.425B, a 27.02% increase year-over-year.

  • Jazz Pharmaceuticals 2023 EBITDA was 1.217B, a 115.85% increase from 2022.
  • Jazz Pharmaceuticals 2022 EBITDA was 0.564B, a 21.97% decline from 2021.
  • Jazz Pharmaceuticals 2021 EBITDA was 0.723B, a 10.12% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Jazz Pharmaceuticals EBITDA 2010-2024 | JAZZ

  • Jazz Pharmaceuticals 2023 EBITDA was 1.217B, a 115.85% increase from 2022.
  • Jazz Pharmaceuticals 2022 EBITDA was 0.564B, a 21.97% decline from 2021.
  • Jazz Pharmaceuticals 2021 EBITDA was 0.723B, a 10.12% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.